Likewise, in the REMAP-CAP trial (Randomized, Embedded, Multifactorial Adaptive Platform Trial), 1557 critically ill adult COVID-19 patients were enrolled and randomized to receive either open-label aspirin (N = 565), a P2Y12 ADPRB (N = 455), or no antiplatelet therapy (control group; N = 529). This evidence concerns the gene P2RY12 and COVID-19.